Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias
Status:
Completed
Trial end date:
2017-01-13
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate whether brimonidine cream can reduce IPL-induced
inflammation in terms of redness, swelling and pain in patients with facial vascular lesions
(telangiectasias). Furthermore, the effect of brimonidine cream on IPL-efficacy is evaluated
one month after final IPL-treatment.
The hypothesis is that brimonidine, which has been proved effective in reduction of
symptomatic erythema in patients with rosacea, also may have the ability to reduce
IPL-induced erythema. Since the potential reduction in erythema is caused by
vasoconstriction, brimonidine may further reduce IPL-induced oedema and pain.